Big data enables the promise of personalised medicineAs our personalised medicine month continues, Joel Haspel and Ketan Patel discuss big data and its role in Share XBig data enables the promise of personalised medicinehttps://pharmaphorum.com/views-and-analysis/big-data-enables-the-promise-of-personalised-medicine/
Spotlight on… multiple sclerosis (MS)In our central nervous system disorders focus month, Andrea Lisher provides us with an overview of multiple sclerosis Share XSpotlight on… multiple sclerosis (MS)https://pharmaphorum.com/views-and-analysis/spotlight-on-multiple-sclerosis-ms/
Pharma gets social: The future of social media in pharmaThis month, Daniel Ghinn shares his opinion on where he sees social media in pharma will be heading Share XPharma gets social: The future of social media in pharmahttps://pharmaphorum.com/views-and-analysis/pharma-gets-social-the-future-of-social-media-in-pharma/
Personalised medicineAnthony Rowbottom explores ‘the new modern era of medicine’ – ‘individual & personalised medicine’. If, like me, you Share XPersonalised medicinehttps://pharmaphorum.com/views-and-analysis/personalised-medicine/
How to enhance patient understanding of medical productsNot every patient is up-to-date with the latest medical and technical terminology. In this article, Ashish Khera discusses Share XHow to enhance patient understanding of medical productshttps://pharmaphorum.com/views-and-analysis/enhance-patient-understanding-of-medical-products/
KOL perspectives: Dr Rajaram RamadossDr. Ramadoss, consultant and Deputy Director of the Department of intensive care at Lyell McEwin Hospital, Australia, shares Share XKOL perspectives: Dr Rajaram Ramadosshttps://pharmaphorum.com/views-and-analysis/syamala-ariyanchira-interviews-dr-rajaram-ramadoss/
Is it time for pharma leaders to focus on positive social and patient impact as business drivers?Anup Soans questions whether it’s time for the industry to re-engage governments, civil society and other stakeholders and Share XIs it time for pharma leaders to focus on positive social and patient impact as business drivers?https://pharmaphorum.com/views-and-analysis/is-it-time-for-pharma-leaders-to-focus-on-positive-social-and-patient-impact-as-business-drivers/
Physician perspectives: Matthew KatzOur October physician perspective comes from Matthew Katz, who shares his thoughts on social media within the healthcare Share XPhysician perspectives: Matthew Katzhttps://pharmaphorum.com/views-and-analysis/physician-perspectives-matthew-katz/
How can we reliably discover the biomarkers we need to achieve stratified medicine?The burgeoning field of stratified / personalised medicine is reliant upon assessing patients using accurate predictive biomarkers – Share XHow can we reliably discover the biomarkers we need to achieve stratified medicine?https://pharmaphorum.com/views-and-analysis/how-can-we-reliably-discover-the-biomarkers-we-need-to-achieve-stratified-medicine/
